Pharmaceutical Preparations Commons^™

Efficacy And Safety Of Vibegron For The Treatment Of Overactive Bladder In Women: A Subgroup Analysis From The Double-Blind, Randomized, Controlled Empowur Trial, Diane K. Newman Dnp, Elizabeth Thomas Ms, Heather Greene Mph, Cornelia Haag-Molkenteller Md, Susann Varano Md

Physician Assistant Studies Faculty Publications

Importance The international phase 3 EMPOWUR trial demonstrated efficacy and safety of vibegron, a newer b3-adrenergic receptor agonist, in adults with overactive bladder (OAB). Women are disproportionately affected by OAB, especially those with bothersome symptoms, such as urge urinary incontinence (UUI). Objective This subgroup analysis from EMPOWUR assessed efficacy and safety of vibegron in women. Study Design In EMPOWUR, patients with OAB were randomized 5:5:4 to 12 weeks of treatment with once-daily vibegron 75 mg, placebo, or tolterodine 4-mg extended release. Efficacy end points included change from baseline at week 12 in mean daily number of micturitions, UUI episodes, and …